These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35652700)

  • 1. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
    Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
    Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
    Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
    Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
    Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
    Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is biological therapy in systemic sclerosis the answer?
    Misra DP; Ahmed S; Agarwal V
    Rheumatol Int; 2020 May; 40(5):679-694. PubMed ID: 31960079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients.
    Morgan K; Woollard C; Beinart D; Host LV; Roddy J
    Intern Med J; 2023 Jul; 53(7):1147-1153. PubMed ID: 35670218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
    Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
    J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study.
    Assassi S; Shao N; Yin Z; Volkmann ER; Zoz DF; Leonard TB
    Medicine (Baltimore); 2022 Aug; 101(32):e29993. PubMed ID: 35960051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
    Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
    J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Asano Y; Oba K; Sato S
    J Dermatol; 2020 Jul; 47(7):796-800. PubMed ID: 32383266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we use nintedanib as early therapy in patients with SSc-ILD?
    Zanatta E; Moccaldi B; Szucs G; Spagnolo P
    Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
    Bruni C; Campochiaro C; de Vries-Bouwstra JK
    Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 19 cases.
    Lebel N; Marie I; Grosjean J; Brevet P; Leclercq M; Dumont A; Levesque H; Benhamou Y; Marcelli C; Lequerre T; Vittecoq O
    Clin Exp Rheumatol; 2024 Aug; 42(8):1536-1540. PubMed ID: 38489323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.